Nabi Down %70 In The Per Market NABI Biopharma announces vaccine fails to meet primary endpoint (NABI) 12.85 : Co announced that StaphVAX failed to meet its primary endpoint in confirmatory Phase III clinical trial. The study found no reduction in S. aureus types 5 and 8 infections in the StaphVAX group as compared to the placebo group. Co will immediately initiate an assessment to determine the factors causing this outcome, including the vaccine target and the quality of the antibody generated by the vaccine. Results will be available within the next few months. StaphVAX was highly immunogenic, confirming that co's vaccine conjugation technology is effective in producing and sustaining high levels of specific antibodies. Co stated, "We are obviously surprised and very disappointed with the results of the StaphVAX confirmatory Phase III trial. While we complete our assessment over the next few months, we will re-focus our capabilities in developing vaccine and antibody products in other areas of significant medical need. This includes advancing other bacterial vaccines in development".